Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 28;10:261. doi: 10.3389/fonc.2020.00261

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Tian, Zhang, Yang, Li, Zhang, Li, Zhang, Mao, Jin and Zhao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Forest plots for the risk ratio of colitis for grade 3–5. (A) Forest plots for the risk ratio of treatment related colitis (PD-1/PD-L1 vs. Docetaxel/Paclitaxel or Chemotherapy). Subgroup analysis was performed according to the composition of chemotherapy in the control group. (B) Forest plots for the risk ratio of treatment related colitis (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. (C) Forest plots for the risk ratio of treatment related colitis (Nivolumab + Ipilimumab vs. Ipilimumab). (D) Forest plots for the risk ratio of treatment related colitis (PD-1 vs. Placebo). (E) Forest plots for the risk ratio of treatment related colitis (Nivolumab vs. Nivolumab + Ipilimumab). Subgroup analysis was performed according to the tumor type. (F) Forest plots for the risk ratio of treatment related colitis (Nivolumab vs. Ipilimumab).